Novozymes A/S (OTCMKTS:NVZMY) Shares Shorted: Short Interest Down 95.5% in September

Novozymes A/S (OTCMKTS:NVZMY) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 546 shares, a decline of 95.5% from the September 15th total of 12,081 shares. Based on an average daily volume of 47,865 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Novozymes A/S stock. Elefante Mark B grew its stake in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,900 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

Novozymes A/S Stock Performance

NVZMY traded up $0.97 on Friday, hitting $65.26. The company’s stock had a trading volume of 24,343 shares, compared to its average volume of 24,596. Novozymes A/S has a 12 month low of $49.90 and a 12 month high of $75.27. The firm has a market cap of $27.05 billion, a P/E ratio of 41.30, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25. The company’s 50 day simple moving average is $66.64 and its 200-day simple moving average is $62.75.

Novozymes A/S (OTCMKTS:NVZMY) last issued its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a net margin of 14.70% and a return on equity of 6.54%. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.27 billion. Analysts forecast that Novozymes A/S will post 2.45 EPS for the current year.

About Novozymes A/S

Novozymes A/S was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing.